Objective: The aim of the study was to compare the hematologic toxicity of gemcitabine between fixed-dose rate (FDR) infusion and 30-minute standard infusion in the treatment of malignancy. Methods: The 25 malignancy patients confirmed by histopathology or cytology received single-agent gemcitabine or gemcitabine in combination with other chemotherapeutic agents. These patients were randomly divided into gemcitabine 1000 mg/m2 on d1, d8 at a rate of 10 mg/m2/min arm (FDR arm) or 30 min arm (standard arm), every 21 days one cycle. Hematologic toxicity was evaluated at the end of each cycle. Results: The 13 of 25 patients received gemcitabine FDR therapy, a total of 28 cycles was completed, and 32 cycles in the others (12 of 25 patients) with the standard arm. All patients were evaluable for hematologic toxicity. The result showed that the grades 3-4 leucopenia was significantly different between the two arms (14.3% vs 0, P < 0.05), and no significant differences of neutropenia, thrombocytopenia and hemoglobin suppression of grades 3-4 (14.3% vs 3.1%, 10.7% vs 3.1%, 3.6% vs 9.4%, P > 0.05, respectively) were observed between the two arms, no grade 4 of hemoglobin suppression was observed. Conclusion: Hematologic toxicity of gemcitabine therapy at a fixed-dose rate for malignancy is tolerable.
STAT3是信号转导子与转录活化子(signal transducer and activator of transcription,STAT)家族的重要成员,在多种恶性肿瘤中高表达,其通过影响肿瘤细胞凋亡、肿瘤血管形成等途径调控肿瘤生长,是目前肿瘤治疗的新的作用靶点。本文就STAT3的结构、激活相关刺激因子、调控肿瘤生长的途径及其作为分子作用靶点的肿瘤治疗前景等内容作一综述。
